NASDAQ · VKTX

Viking Therapeutics, Inc.

$34.87 +$0.08 (+0.23%) 1D Pre-market

Key Metrics

$4.04B
Market cap
P/E · TTM
$0
Revenue · TTM
−$472.34M
Net income
EPS · TTM $-4.21
Dividend yield
Free cash flow
Beta · 1Y 1.25
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 23
    The stock moved +11.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 23
  • Feb 5
    The stock moved -11.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$4.04B
Enterprise value
Shares outstanding116.1M
52-wk range$22.96 – $43.15
Avg volume · 20D2.8M
Net cash
Book value / share$4.48
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Viking Therapeutics, Inc.
IPO dateApr 29, 2015
Employees59

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -68.3% · —

Financial Health

Current ratio5.72
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$501.88M

Cash Flow · TTM

Operating CF −$340.33M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

18.7
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings